Testing effectiveness (Phase 2)Ended earlyNCT02314052
What this trial is testing
Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
Who this might be right for
Hepatocellular Carcinoma
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company 21